IRONMAN

Investigating whether treating iron deficiency with injections can prevent people with heart failure from being admitted to hospital and improve their overall outcomes.

Further reading

• Kalra, P.R., Cleland, J.G.F., Petrie, M.C., Thomson, E.A., Kalra, P.A., Squire, I.B., Ahmed, F.Z., Al-Mohammad, A., Cowburn, P.J., Foley, P.W.X., Graham, F.J., Japp, A.G., Lane, R.E., Lang, N.N., Ludman, A.J., Macdougall, I.C., Pellicori, P., Ray, R., Robertson, M. and Seed, A. (2022). Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. doi:10.1016/s0140-6736(22)02083-9.

‌